全髋关节置换术前的镇痛、并发症与资源利用:曲马多与其他术前阿片类药物相比风险更低
该回顾性队列研究利用Truven MarketScan数据库分析198,357例初次全髋关节置换术患者,按术前用药分为阿片未暴露、仅曲马多和非曲马多阿片类三组。仅曲马多组并发症和翻修率与阿片未暴露组相似,但急诊就诊、再入院和非居家出院略高;与非曲马多阿片类相比,仅曲马多组多数并发症(包括翻修手术)风险显著更低。作者认为曲马多是全髋关节置换术前合适的镇痛药。
要点
- 仅曲马多组与阿片未暴露组并发症和翻修率无显著差异。
- 仅曲马多组较阿片未暴露组急诊就诊、再入院和非居家出院风险略高。
- 仅曲马多组较非曲马多阿片类组多数并发症(含翻修手术)风险显著更低。
核心结论
- 术前仅使用曲马多与非曲马多阿片类相比术后风险更低,与阿片未暴露相似。
- 作者认为曲马多是全髋关节置换术前合适的镇痛药。
研究设计与样本
- 回顾性队列研究,使用Truven MarketScan数据库,纳入198,357例成人初次全髋关节置换术患者。
- 按术前阿片类药物分为阿片未暴露组(106,768例)、仅曲马多组(18,694例)和非曲马多阿片类组(含或不含曲马多)。
- 收集人口学、合并症和90天并发症,比较3年翻修率,进行单变量和多变量分析,并分析术前处方趋势。
主要发现
- 仅曲马多组与阿片未暴露组并发症和翻修手术率相似(P > .05)。
- 仅曲马多组较阿片未暴露组急诊就诊略高(OR 1.06;95%CI 1.01-1.12;P = .027)。
- 仅曲马多组较阿片未暴露组再入院略高(OR 1.16;95%CI 1.09-1.22;P < .001)。
- 仅曲马多组较阿片未暴露组非居家出院略高(OR 1.07;95%CI 1.02-1.12;P = .010)。
- 仅曲马多组较非曲马多阿片类组多数所查并发症(包括翻修手术)的比值显著更低(P < .05)。
关键数值与推荐
- 仅曲马多组 vs 阿片未暴露组:急诊就诊 OR 1.06(95%CI 1.01-1.12;P = .027),仅曲马多组较高。
- 仅曲马多组 vs 阿片未暴露组:再入院 OR 1.16(95%CI 1.09-1.22;P < .001),仅曲马多组较高。
- 仅曲马多组 vs 阿片未暴露组:非居家出院 OR 1.07(95%CI 1.02-1.12;P = .010),仅曲马多组较高。
- 仅曲马多组 vs 非曲马多阿片类组:多数所查并发症(包括翻修手术)的比值显著更低(P < .05)。
- 2009年至2018年,术前阿片类药物处方比例下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative opioid use is known to be detrimental to outcomes after total hip arthroplasty (THA). This is concerning as multiple societies recommend tramadol for the management of arthritis. The purpose of this study was to determine if tramadol is associated with postoperative complications, increased resource utilization, and revision when compared with patients receiving nontramadol opioids (NTOs) and those who are opioid naive (ON). METHODS: This is a retrospective cohort study using the Truven MarketScan databases (Truven Health, Ann Arbor, MI). Adult patients undergoing primary THA were identified and divided into 4 cohorts based on preoperative opioid medications (ie, ON, tramadol-only [TO], or NTOs; ±tramadol). Demographics, comorbidities, and 90-day complications were collected and compared between cohorts. Revision rates were compared at 3 years. Univariate and multivariate analyses were performed. Finally, preoperative prescription patterns were trended during the study period. RESULTS: About 198,357 patients, including 18,694 TO and 106,768 ON, were identified. Compared with ON, TO patients had similar rates of complications and revision surgery (P > .05) but had slightly higher emergency department visits (odds ratio [OR], 1.06; 95% confidence interval [95% CI], 1.01-1.12; P = .027), readmissions (OR, 1.16; 95% CI, 1.09-1.22; P < .001), and nonhome discharges (OR, 1.07; 95% CI, 1.02-1.12; P = .010). TO patients had significantly lower odds of incurring most examined complications, including revision surgery, when compared with NTO (P < .05). From 2009 to 2018, the proportion of patients prescribed preoperative opioids decreased. CONCLUSION: Preoperative TO is associated with less postoperative risk than NTO use and is similar to opioid naivety. Fortunately, the number of patients receiving preoperative NTOs appears to be decreasing. Our results support tramadol as an appropriate pre-THA analgesic.
引用
- Wilson JM, Schwartz AM, Farley KX, et al. Preoperative Analgesia, Complications, and Resource Utilization After Total Hip Arthroplasty: Tramadol Is Associated With Less Risk Than Other Preoperative Opioid Medications. J Arthroplasty. 2020. PMID: 32788062. doi:10.1016/j.arth.2020.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。